Solid Biosciences Inc. (NASDAQ:SLDB) Receives $16.00 Consensus Target Price from Analysts

Shares of Solid Biosciences Inc. (NASDAQ:SLDB) have received a consensus rating of “Moderate Buy” from the twelve research firms that are currently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating and eleven have issued a buy rating on the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $16.0909.

Several analysts have weighed in on the stock. Wedbush reaffirmed an “outperform” rating and set a $14.00 price objective on shares of Solid Biosciences in a research note on Wednesday, March 11th. Needham & Company LLC reiterated a “buy” rating and issued a $19.00 target price on shares of Solid Biosciences in a research note on Friday, March 20th. Chardan Capital reissued a “buy” rating and issued a $15.00 target price on shares of Solid Biosciences in a report on Friday, March 20th. HC Wainwright restated a “buy” rating and set a $20.00 price target on shares of Solid Biosciences in a research report on Monday. Finally, Guggenheim began coverage on Solid Biosciences in a report on Friday, March 20th. They set a “buy” rating and a $26.00 price target for the company.

Insider Activity at Solid Biosciences

In other news, Director Ilan Ganot sold 7,205 shares of the firm’s stock in a transaction on Wednesday, February 4th. The stock was sold at an average price of $6.44, for a total value of $46,400.20. Following the completion of the sale, the director directly owned 25,271 shares in the company, valued at approximately $162,745.24. This trade represents a 22.19% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, insider Gabriel Brooks sold 12,616 shares of the firm’s stock in a transaction on Wednesday, February 4th. The shares were sold at an average price of $6.44, for a total value of $81,247.04. Following the completion of the sale, the insider owned 84,092 shares of the company’s stock, valued at approximately $541,552.48. This trade represents a 13.05% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 597,672 shares of company stock valued at $3,816,546. 1.90% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Solid Biosciences

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Legal & General Group Plc raised its stake in shares of Solid Biosciences by 208.6% in the second quarter. Legal & General Group Plc now owns 6,011 shares of the company’s stock worth $29,000 after acquiring an additional 4,063 shares during the last quarter. Ameritas Investment Partners Inc. grew its stake in shares of Solid Biosciences by 205.5% during the second quarter. Ameritas Investment Partners Inc. now owns 6,740 shares of the company’s stock valued at $33,000 after purchasing an additional 4,534 shares during the last quarter. Creative Planning bought a new stake in shares of Solid Biosciences during the second quarter valued at approximately $57,000. Russell Investments Group Ltd. increased its holdings in shares of Solid Biosciences by 142.0% in the third quarter. Russell Investments Group Ltd. now owns 10,211 shares of the company’s stock valued at $63,000 after purchasing an additional 5,991 shares in the last quarter. Finally, Police & Firemen s Retirement System of New Jersey increased its holdings in shares of Solid Biosciences by 233.8% in the second quarter. Police & Firemen s Retirement System of New Jersey now owns 15,113 shares of the company’s stock valued at $74,000 after purchasing an additional 10,585 shares in the last quarter. Institutional investors and hedge funds own 81.46% of the company’s stock.

Solid Biosciences News Roundup

Here are the key news stories impacting Solid Biosciences this week:

• Positive Sentiment: JPMorgan raised its price target on SLDB to $12.00 from $11.00 and moved the stock to an “Overweight” stance — implying roughly a 66% upside from the referenced $7.23 level. This upgrade signals increased conviction from a large Wall Street shop and likely contributed to buying interest. Benzinga
• Positive Sentiment: HC Wainwright reiterated a “Buy” and lifted near-term EPS forecasts across multiple quarters and fiscal years (Q1–Q4 2026 and FY2026) while maintaining a $20 price target. They also issued later-year upside (FY2029–FY2030 projected profitability), trimming FY2026 losses significantly vs. prior forecasts — an analyst view that supports a more constructive growth/profitability outlook. Solid Biosciences Earns Buy Rating from HC Wainwright
• Neutral Sentiment: Reported short-interest data for March appears anomalous (shows 0 shares and NaN changes). Because the figures are likely erroneous or incomplete, they provide no clear signal about potential short-squeeze dynamics or bearish positioning at this time.

Solid Biosciences Stock Performance

Shares of NASDAQ:SLDB opened at $7.23 on Monday. The company’s fifty day moving average is $6.53 and its 200-day moving average is $5.82. Solid Biosciences has a 52 week low of $2.41 and a 52 week high of $8.72. The company has a market capitalization of $563.29 million, a PE ratio of -3.58 and a beta of 2.65.

Solid Biosciences (NASDAQ:SLDB) last announced its earnings results on Thursday, March 19th. The company reported ($0.50) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.51) by $0.01. On average, analysts forecast that Solid Biosciences will post -2.84 EPS for the current year.

About Solid Biosciences

Solid Biosciences Inc is a clinical‐stage biotechnology company focused on the development of therapies for Duchenne muscular dystrophy (DMD), a rare genetic disorder characterized by progressive muscle degeneration. The company’s primary approach centers on gene replacement and gene editing technologies designed to restore functional dystrophin protein in patients lacking this critical muscle‐stabilizing protein.

Solid’s lead investigational therapy, SGT‐001, is a micro‐dystrophin gene therapy candidate engineered to deliver a shortened but functional form of the dystrophin gene using an adeno‐associated virus (AAV) vector.